{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:21:16Z","timestamp":1774354876984,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.bcp.2005.06.029","type":"journal-article","created":{"date-parts":[[2005,10,14]],"date-time":"2005-10-14T11:14:48Z","timestamp":1129288488000},"page":"1653-1663","source":"Crossref","is-referenced-by-count":21,"title":["Fibrates inhibit aldose reductase activity in the forward and reverse reactions"],"prefix":"10.1016","volume":"70","author":[{"given":"Ganesaratnam K.","family":"Balendiran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balakrishnan","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bcp.2005.06.029_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJM197304192881609","article-title":"The sorbitol pathway and the complications of diabetes","volume":"288","author":"Gabbay","year":"1973","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2005.06.029_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-198600322-00007","article-title":"Pharmacological inhibition of aldose reductase in human diabetic neuropathy","volume":"32","author":"Jaspan","year":"1986","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.bcp.2005.06.029_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM198703053161007","article-title":"Sorbitol, phosphoinositides, and sodium\u2013potassium-ATPase in the pathogenesis of diabetic complications","volume":"316","author":"Greene","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bcp.2005.06.029_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/med.2610080302","article-title":"The role of aldose reductase in the development of diabetic complications","volume":"8","author":"Kador","year":"1988","journal-title":"Med Res Rev"},{"issue":"4","key":"10.1016\/j.bcp.2005.06.029_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/dmr.5610040403","article-title":"The involvement of aldose reductase in diabetic complications","volume":"4","author":"Kinoshita","year":"1988","journal-title":"Diab Metab Rev"},{"key":"10.1016\/j.bcp.2005.06.029_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00044011-199815020-00005","article-title":"Effect of AR Inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy","volume":"15","author":"Brankston","year":"1998","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1016\/j.bcp.2005.06.029_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1755.2001.00788.x","article-title":"Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy","volume":"60","author":"Hodgkinson","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.bcp.2005.06.029_bib8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/184194b0","article-title":"Formation of polyols by the lens of the rat with sugar cataract","volume":"184","author":"Van Heyningen","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2005.06.029_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0006-3002(60)90086-X","article-title":"The mechanism of the formation of seminal fructose and fetal fructose","volume":"37","author":"Hers","year":"1960","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.bcp.2005.06.029_bib10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0014-4835(90)90107-6","article-title":"The role of lens epithelium in sugar cataract formation","volume":"50","author":"Robison","year":"1990","journal-title":"Exp Eye Res"},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2005.06.029_bib11","doi-asserted-by":"crossref","first-page":"B62","DOI":"10.1007\/BF03168189","article-title":"Epidemiology and genetics of diabetic complications","volume":"40","author":"Newfield","year":"1997","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2005.06.029_bib12","doi-asserted-by":"crossref","first-page":"B78","DOI":"10.1007\/BF03168193","article-title":"Cardiovascular complications of diabetes","volume":"40","author":"Caprio","year":"1997","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.bcp.2005.06.029_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0168-8227(99)00015-7","article-title":"Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus","volume":"43","author":"Ikeda","year":"1999","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.bcp.2005.06.029_bib14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(62)92423-6","article-title":"Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate","volume":"1","author":"Throp","year":"1962","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2005.06.029_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","article-title":"Clinical pharmacokinetics of fibric acid derivatives (fibrates)","volume":"34","author":"Miller","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.bcp.2005.06.029_bib16","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.2337\/diabetes.51.12.3486","article-title":"Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients","volume":"51","author":"Forcheron","year":"2002","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.bcp.2005.06.029_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1172\/JCI107904","article-title":"Inhibition of hormone-stimulated lipolysis by clofibrate. A possible mechanism for its hypolipidemic action","volume":"55","author":"D\u2019Costa","year":"1975","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.bcp.2005.06.029_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00544015","article-title":"Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects","volume":"25","author":"Heller","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"2\/3","key":"10.1016\/j.bcp.2005.06.029_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0021-9150(89)90075-0","article-title":"Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration","volume":"77","author":"Malmendier","year":"1989","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.bcp.2005.06.029_bib20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2337\/diacare.13.8.855","article-title":"Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM","volume":"13","author":"Jones","year":"1990","journal-title":"Diab Care"},{"issue":"6","key":"10.1016\/j.bcp.2005.06.029_bib21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1172\/JCI115535","article-title":"Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia","volume":"88","author":"Mann","year":"1991","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2005.06.029_bib22","first-page":"S34","article-title":"Mechanism of action of fibrates","volume":"69","author":"Shepherd","year":"1993","journal-title":"Postgrad Med J"},{"issue":"2","key":"10.1016\/j.bcp.2005.06.029_bib23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1172\/JCI118118","article-title":"Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor","volume":"96","author":"Vu-Dac","year":"1995","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.bcp.2005.06.029_bib24","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI118687","article-title":"Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice","volume":"97","author":"Berthou","year":"1996","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.bcp.2005.06.029_bib25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression","volume":"37","author":"Schoonjans","year":"1996","journal-title":"J Lipid Res"},{"issue":"45","key":"10.1016\/j.bcp.2005.06.029_bib26","doi-asserted-by":"crossref","first-page":"28210","DOI":"10.1074\/jbc.272.45.28210","article-title":"Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators","volume":"272","author":"Martin","year":"1997","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.bcp.2005.06.029_bib27","first-page":"912","article-title":"Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group","volume":"81","author":"Fruchart","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.bcp.2005.06.029_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein\u2013dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"issue":"2","key":"10.1016\/j.bcp.2005.06.029_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-4838(91)99006-E","article-title":"Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system","volume":"1078","author":"Nishimura","year":"1991","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"10.1016\/j.bcp.2005.06.029_bib30","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/0006-2952(92)90693-D","article-title":"Does sorbinil bind to the substrate binding site of aldose reductase?","volume":"44","author":"Liu","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2005.06.029_bib31","first-page":"273","article-title":"Determining the chemical mechanisms of enzyme-catalyzed reactions by kinetic studies","volume":"45","author":"Cleland","year":"1977","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"10.1016\/j.bcp.2005.06.029_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0076-6879(79)63008-2","article-title":"Statistical analysis of enzyme kinetic data","volume":"63","author":"Cleland","year":"1979","journal-title":"Meth Enzymol"},{"issue":"8","key":"10.1016\/j.bcp.2005.06.029_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1358\/mf.2001.23.8.662134","article-title":"The role of aldose reductase inhibitors in diabetic complications: recent trends","volume":"23","author":"Kaul","year":"2001","journal-title":"Meth Find Exp Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.bcp.2005.06.029_bib34","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1517\/13543784.8.12.2095","article-title":"Aldose reductase inhibitors: therapeutic implications for diabetic complications","volume":"8","author":"Oates","year":"1999","journal-title":"Expert Opin Invest Drugs"},{"issue":"2","key":"10.1016\/j.bcp.2005.06.029_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1074\/mcp.M300119-MCP200","article-title":"Proteomic analysis of oxidative stress-resistant cells: a specific role for aldose reductase overexpression in cytoprotection","volume":"3","author":"Keightley","year":"2004","journal-title":"Mol Cell Proteomics"},{"issue":"8 Suppl 3","key":"10.1016\/j.bcp.2005.06.029_bib36","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1097\/01.ASN.0000077408.15865.06","article-title":"Contribution of polyol pathway to diabetes-induced oxidative stress","volume":"14","author":"Chung","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.bcp.2005.06.029_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1096\/fasebj.13.1.23","article-title":"Contributions of polyol pathway to oxidative stress in diabetic cataract","volume":"13","author":"Lee","year":"1999","journal-title":"FASEB J"},{"issue":"7","key":"10.1016\/j.bcp.2005.06.029_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1172\/JCI4711","article-title":"Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis","volume":"103","author":"Rittner","year":"1999","journal-title":"J Clin Invest"},{"issue":"51","key":"10.1016\/j.bcp.2005.06.029_bib39","doi-asserted-by":"crossref","first-page":"53395","DOI":"10.1074\/jbc.M403416200","article-title":"Aldose reductase-catalyzed reduction of aldehyde phospholipids","volume":"279","author":"Srivastava","year":"2004","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.bcp.2005.06.029_bib40","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1124\/mol.61.5.1184","article-title":"Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes","volume":"61","author":"Chang","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.bcp.2005.06.029_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00045391-199603000-00007","article-title":"The effect of urinary pH and flow rate on the renal elimination of zopolrestat and zopolrestat glucuronide in humans","volume":"3","author":"Inskeep","year":"1996","journal-title":"Am J Ther"},{"issue":"1","key":"10.1016\/j.bcp.2005.06.029_bib42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0006-291X(70)91066-1","article-title":"Glucose utilization by the polyol pathway in human erythrocytes","volume":"40","author":"Morrison","year":"1970","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"10.1016\/j.bcp.2005.06.029_bib43","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1016\/S0021-9258(17)34567-2","article-title":"Conversion of glucose to sorbitol and fructose by liver-derived cells in culture","volume":"253","author":"Levine","year":"1978","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.bcp.2005.06.029_bib44","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2337\/diab.33.2.196","article-title":"Direct measurement of polyol pathway activity in the ocular lens","volume":"33","author":"Gonzalez","year":"1984","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.bcp.2005.06.029_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0165-6147(94)90010-8","article-title":"Aldose reductase inhibitors and their potential for the treatment of diabetic complications","volume":"15","author":"Tomlinson","year":"1994","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.bcp.2005.06.029_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0031-6997(24)01347-4","article-title":"Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications","volume":"50","author":"Yabe-Nishimura","year":"1998","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.bcp.2005.06.029_bib47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0021-9258(18)55896-8","article-title":"Effect of fructose on lipogenesis from lactate and acetate in diabetic liver","volume":"194","author":"Baker","year":"1952","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2005.06.029_bib48","first-page":"A39","article-title":"De novo lipogenesis during fasting and oral fructose ingestion in lean and obese hyperinsulinemic subjects","volume":"42","author":"Schwarz","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2005.06.029_bib49","first-page":"52A","article-title":"Effect of fructose ingestion on glucose production (GP) and de novo lipogenesis (DNL) in normal and hyperinsulinemic obese humans","volume":"43","author":"Schwarz","year":"1994","journal-title":"Diabetes"},{"issue":"Suppl 5","key":"10.1016\/j.bcp.2005.06.029_bib50","doi-asserted-by":"crossref","first-page":"754S","DOI":"10.1093\/ajcn\/58.5.754S","article-title":"Intermediary metabolism of fructose","volume":"58","author":"Mayes","year":"1993","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"10.1016\/j.bcp.2005.06.029_bib51","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJM198903163201105","article-title":"Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance","volume":"320","author":"Zavaroni","year":"1989","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bcp.2005.06.029_bib52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/ajcn\/61.4.787","article-title":"Postprandial triglyceride and retinyl ester responses to oral fat: effects of fructose","volume":"61","author":"Jeppesen","year":"1995","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.bcp.2005.06.029_bib53","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/ajcn\/50.5.1008","article-title":"Day-long glucose, insulin, and fructose responses of hyperinsulinemic and nonhyperinsulinemic men adapted to diets containing either fructose or high-amylose cornstarch","volume":"50","author":"Reiser","year":"1989","journal-title":"Am J Clin Nutr"},{"issue":"Pt 3","key":"10.1016\/j.bcp.2005.06.029_bib54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1042\/bj2820753","article-title":"Mechanisms of fructose-induced hypertriglyceridaemia in the rat. Activation of hepatic pyruvate dehydrogenase through inhibition of pyruvate dehydrogenase kinase","volume":"282","author":"Park","year":"1992","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.bcp.2005.06.029_bib55","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/ajcn\/72.5.1128","article-title":"Effects of dietary fructose on plasma lipids in healthy subjects","volume":"72","author":"Bantle","year":"2000","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.bcp.2005.06.029_bib56","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/ajcn\/76.5.911","article-title":"Fructose, weight gain, and the insulin resistance syndrome","volume":"76","author":"Elliott","year":"2002","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.bcp.2005.06.029_bib57","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/en.2003-1167","article-title":"High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation","volume":"145","author":"Kelley","year":"2004","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.bcp.2005.06.029_bib58","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1016\/S0021-9258(19)50457-4","article-title":"Studies on pig muscle aldose reductase. Kinetic mechanism and evidence for a slow conformational change upon coenzyme binding","volume":"267","author":"Kubiseski","year":"1992","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.bcp.2005.06.029_bib59","doi-asserted-by":"crossref","first-page":"9847","DOI":"10.1073\/pnas.90.21.9847","article-title":"Refined 1.8\u00c5 structure of human aldose reductase complexed with the potent inhibitor zopolrestat","volume":"90","author":"Wilson","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.bcp.2005.06.029_bib60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF00569934","article-title":"Relationship between myoinositol influx and lipids in diabetic neuropathy","volume":"30","author":"Simmons","year":"1993","journal-title":"Acta Diabetol"},{"issue":"3","key":"10.1016\/j.bcp.2005.06.029_bib61","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/jnnp.66.3.410a","article-title":"Severe toxic neuropathy due to fibrates","volume":"66","author":"Corcia","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7991","key":"10.1016\/j.bcp.2005.06.029_bib62","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(76)90564-X","article-title":"Clofibrate-induced myopathy and neuropathy","volume":"2","author":"Gabriel","year":"1976","journal-title":"Lancet"},{"issue":"6959","key":"10.1016\/j.bcp.2005.06.029_bib63","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/bmj.309.6959.929b","article-title":"Peripheral neuropathy with bezafibrate","volume":"309","author":"Ellis","year":"1994","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.bcp.2005.06.029_bib64","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/01.CIR.95.2.324","article-title":"Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease","volume":"95","author":"Andrews","year":"1997","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2005.06.029_bib65","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11886-999-0026-8","article-title":"Fibrates and high-dose statins to prevent coronary heart disease events","volume":"1","author":"Jones","year":"1999","journal-title":"Curr Cardiol Rep"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2005.06.029_bib66","first-page":"S139","article-title":"Fibrates in the secondary prevention of ischemic cardiopathy","volume":"71","author":"Posadas Romero","year":"2001","journal-title":"Arch Cardiol Mex"},{"issue":"2","key":"10.1016\/j.bcp.2005.06.029_bib67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/diab.46.2.292","article-title":"Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury","volume":"46","author":"Ramasamy","year":"1997","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.bcp.2005.06.029_bib68","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/01.RES.0000029970.97247.57","article-title":"Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning","volume":"91","author":"Shinmura","year":"2002","journal-title":"Circ Res"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295205005903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295205005903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T23:03:43Z","timestamp":1736031823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295205005903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0006295205005903"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2005.06.029","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}